Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
KVUE Stock Forecast 2026-2027
$17.71
Current Price
$34.00B
Market Cap
Buy 2
Hold 12
Sell 0
Wall St Analyst Ratings
Distance to KVUE Price Targets
+29.9%
To High Target of $23.00
+7.3%
To Median Target of $19.00
+1.6%
To Low Target of $18.00
KVUE Price Momentum
+2.1%
1 Week Change
+0.7%
1 Month Change
-18.5%
1 Year Change
+2.7%
Year-to-Date Change
-22.6%
From 52W High of $22.87
+26.3%
From 52W Low of $14.02
📊 TOP ANALYST CALLS
Did KVUE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Kenvue is one of their latest high-conviction picks.
Latest KVUE Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, KVUE has a neutral consensus with a median price target of $19.00 (ranging from $18.00 to $23.00). The overall analyst rating is Buy (6.4/10). Currently trading at $17.71, the median forecast implies a 7.3% upside. This outlook is supported by 2 Buy, 12 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Lauren Lieberman at Barclays, suggesting a 1.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KVUE Analyst Ratings
2
Buy
12
Hold
0
Sell
KVUE Price Target Range
Low
$18.00
Average
$19.00
High
$23.00
Current: $17.71
Latest KVUE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KVUE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 15, 2026 | Citigroup | Filippo Falorni | Neutral | Maintains | $19.00 |
| Apr 14, 2026 | Barclays | Lauren Lieberman | Equal-Weight | Maintains | $18.00 |
| Apr 7, 2026 | UBS | Neutral | Maintains | $N/A | |
| Mar 6, 2026 | Barclays | Equal-Weight | Maintains | $N/A | |
| Feb 18, 2026 | Canaccord Genuity | Hold | Maintains | $N/A | |
| Feb 18, 2026 | Citigroup | Neutral | Maintains | $N/A | |
| Feb 18, 2026 | UBS | Neutral | Maintains | $N/A | |
| Jan 30, 2026 | Jefferies | Hold | Downgrade | $N/A | |
| Nov 10, 2025 | Barclays | Equal-Weight | Maintains | $N/A | |
| Oct 29, 2025 | Canaccord Genuity | Hold | Downgrade | $N/A | |
| Oct 27, 2025 | Jefferies | Buy | Maintains | $N/A | |
| Oct 10, 2025 | JP Morgan | Overweight | Maintains | $N/A | |
| Oct 9, 2025 | Citigroup | Neutral | Maintains | $N/A | |
| Oct 8, 2025 | B of A Securities | Buy | Maintains | $N/A | |
| Oct 8, 2025 | UBS | Neutral | Maintains | $N/A | |
| Oct 2, 2025 | Goldman Sachs | Neutral | Maintains | $N/A | |
| Oct 1, 2025 | Barclays | Equal-Weight | Maintains | $N/A | |
| Sep 26, 2025 | Rothschild & Co | Buy | Upgrade | $N/A | |
| Sep 23, 2025 | Evercore ISI Group | In-Line | Maintains | $N/A | |
| Sep 16, 2025 | Citigroup | Neutral | Maintains | $N/A |
Kenvue Inc. (KVUE) Competitors
The following stocks are similar to Kenvue based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Kenvue Inc. (KVUE) Financial Data
Kenvue Inc. has a market capitalization of $34.00B with a P/E ratio of 21.1x. The company generates $15.29B in trailing twelve-month revenue with a 10.6% profit margin.
Revenue growth is +4.5% quarter-over-quarter, while maintaining an operating margin of +21.6% and return on equity of +15.7%.
Valuation Metrics
Market Cap
$34.00B
Enterprise Value
$41.73B
P/E Ratio
21.1x
PEG Ratio
0.4x
Price/Sales
2.2x
Growth & Margins
Revenue Growth (YoY)
+4.5%
Gross Margin
+58.9%
Operating Margin
+21.6%
Net Margin
+10.6%
EPS Growth
+47.2%
Financial Health
Cash/Price Ratio
+3.2%
Current Ratio
1.0x
Debt/Equity
83.0x
ROE
+15.7%
ROA
+7.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Kenvue Inc. (KVUE) Business Model
About Kenvue Inc.
What They Do
Develops and markets consumer healthcare products.
Business Model
Kenvue Inc. generates revenue by developing, manufacturing, and marketing a wide range of over-the-counter healthcare and personal care products. The company operates through specialized segments, including self care, skin health and beauty, and essential health, which allows it to effectively cater to diverse consumer needs and leverage scale in the market.
Additional Information
Kenvue's portfolio includes well-known brands like Tylenol, Listerine, and Neutrogena, making it a significant player in the consumer defensive sector. The company was founded in 2023 and is headquartered in Summit, New Jersey, targeting staple purchases across various retail channels including pharmacies and e-commerce platforms.
Company Information
Sector
Consumer Defensive
Industry
Household & Personal Products
Employees
21,780
CEO
Mr. Kirk L. Perry
Country
United States
IPO Year
2023
Website
www.kenvue.comKenvue Inc. (KVUE) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Best Consumer Dividend Stocks to Buy Now: HAS, KVUE, MOV
Here are three top-rated consumer dividend stocks that have yields above 3% and have made their way onto the coveted Zacks Rank #1 (Strong Buy) list.
Jun 04, 2026
By Shaun Pruitt
Investment Ideas
Is Colgate Too Dependent on Pricing Actions for Revenue Growth?
CL balances pricing and volume growth as emerging markets and innovation support sales momentum.
May 27, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Earnings beats are particularly significant for underperforming stocks, indicating potential recovery and renewed investor interest.
Why It Matters
Earnings beats in previously abandoned stocks signal potential turnaround and recovery, attracting investor interest and possibly leading to price appreciation.
Source: Market Watch
Market Sentiment:
Positive
Quick Summary
Three top-rated consumer dividend stocks with yields over 3% have received a Zacks Rank #1 (Strong Buy) rating.
Why It Matters
High-yield consumer dividend stocks with strong ratings indicate potential for income and capital appreciation, attracting income-focused investors and enhancing portfolio stability.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Investors in Consumer Products - Staples should consider both Kenvue (KVUE) and L'Oreal SA (LRLCY) for potential value opportunities.
Why It Matters
The comparison between Kenvue and L'Oreal highlights potential investment opportunities in Consumer Products, guiding value investors toward more promising stocks.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Diamondback Energy shares increased due to rising oil prices. Capital One underperformed after acquiring Brex, while Kimberly-Clark was added to the portfolio after acquiring Kenvue.
Why It Matters
Rising oil prices boost Diamondback Energy's value, enhancing sector optimism. Capital One's weak performance post-acquisition could signal risks, while Kimberly-Clark's strategic buy may present a buying opportunity.
Source: Seeking Alpha
Market Sentiment:
Neutral
Best Income Stocks to Buy for May 26th
13 days ago
Quick Summary
GECC, KVUE, and TNET have been rated as Zacks Rank #1 (Strong Buy) income stocks as of May 26, 2026.
Why It Matters
GECC, KVUE, and TNET being ranked as Strong Buy indicates strong growth potential and positive analyst sentiment, signaling attractive investment opportunities.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
In Q1 2026, the Diamond Hill Select Strategy fell 0.52%, outperforming the Russell 3000 Index's 3.96% decline. Regal Rexnord showed strong orders, while Capital One underperformed post-Brex acquisition.
Why It Matters
The Diamond Hill Select Strategy's outperformance against the Russell 3000 highlights its effective management, while Regal Rexnord's strong orders signal growth potential, contrasting with Capital One's struggles post-acquisition.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About KVUE Stock
What is Kenvue Inc.'s (KVUE) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Kenvue Inc. (KVUE) has a median price target of $19.00. The highest price target is $23.00 and the lowest is $18.00.
Is KVUE stock a good investment in 2026?
According to current analyst ratings, KVUE has 2 Buy ratings, 12 Hold ratings, and 0 Sell ratings. The stock is currently trading at $17.71. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for KVUE stock?
Wall Street analysts predict KVUE stock could reach $19.00 in the next 12 months. This represents a 7.3% increase from the current price of $17.71. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Kenvue Inc.'s business model?
Kenvue Inc. generates revenue by developing, manufacturing, and marketing a wide range of over-the-counter healthcare and personal care products. The company operates through specialized segments, including self care, skin health and beauty, and essential health, which allows it to effectively cater to diverse consumer needs and leverage scale in the market.
What is the highest forecasted price for KVUE Kenvue Inc.?
The highest price target for KVUE is $23.00 from at , which represents a 29.9% increase from the current price of $17.71.
What is the lowest forecasted price for KVUE Kenvue Inc.?
The lowest price target for KVUE is $18.00 from Lauren Lieberman at Barclays, which represents a 1.6% increase from the current price of $17.71.
What is the overall KVUE consensus from analysts for Kenvue Inc.?
The overall analyst consensus for KVUE is neutral. Out of 3 Wall Street analysts, 2 rate it as Buy, 12 as Hold, and 0 as Sell, with a median price target of $19.00.
How accurate are KVUE stock price projections?
Stock price projections, including those for Kenvue Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 8, 2026 3:04 AM UTC